Frequently Asked Questions

Yes, most international patients require a medical visa (M visa). CancerCareE provides invitation letters from hospitals to support visa applications. Processing takes 5-10 days.

CAR-T: 4-6 weeks. TIL therapy: 6-8 weeks. Bone marrow transplant: 2-3 months. Follow-up can be done remotely.

Yes. We arrange family visas, shared accommodation, and provide translators. One companion is recommended for support.

Advanced treatments offer: Enhanced Effectiveness, Personalized Approach, Reduced Side Effects, and Increased Survival Rates compared to traditional chemotherapy and radiation.

Yes. NK cell therapy is offered in multiple hospitals in Beijing, Shanghai, and Guangzhou with success rates of 60-80% for solid tumors.

Options include hospital VIP wards, serviced apartments near the hospital, or 5-star hotels. All include daily transport to hospital.

Yes. 24/7 medical translators (English, Arabic, Russian, Turkish) accompany patients to all appointments.

Autologous BMT: $30,000-$60,000. Allogeneic BMT: $80,000-$150,000 including donor search and hospital stay.

Hospital stay: 4-6 weeks. Full recovery: 3-6 months. Regular follow-ups required.

Chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for a variety of cancers. The idea is to remove the patient's T cells and genetically engineer them to express a chimeric antigen receptor (CAR) that recognises a specific tumour-associated antigen (TAA). As a result, when the CAR-expressing T-cells are reintroduced into the patient's body, they will target and eliminate the TAA-expressing tumour cells.

CAR-T therapy in China typically costs between $50,000 to $150,000 depending on the hospital, type of cancer, and specific treatment protocol required.

Top hospitals include Beijing Cancer Hospital, Peking University Cancer Hospital, Shanghai Cancer Center, and Guangzhou Nanfang Hospital.

The entire process takes 3-6 weeks: 1 week for cell collection, 2-3 weeks for manufacturing, and 1-2 weeks for infusion and monitoring.

Success rates vary by cancer type. For lymphoma: 70-90% complete response. For leukemia: 80-95% remission. Individual results depend on cancer stage and patient health.

Common side effects include cytokine release syndrome (CRS), neurotoxicity, fever, low blood pressure, and fatigue. Most are manageable with medication.

Yes. CancerCareE assists international patients with medical visas, translation, accommodation, and full treatment coordination.

TIL (Tumor-Infiltrating Lymphocyte) therapy is a form of immunotherapy where T-cells from the patient's tumor are harvested, expanded in a lab, and then reinfused into the patient to attack cancer cells.

Effective for melanoma, cervical cancer, lung cancer, and some solid tumors. Clinical trials ongoing for others.

Fill the online evaluation form, upload medical reports, and our team will arrange a video consultation with Chinese oncologists within 24-48 hours.

Required: Passport, medical reports, biopsy results, imaging scans, blood tests, and referral letter. CancerCareE helps prepare all documents.

Yes. Many advanced therapies (CAR-NK, Gamma Delta T, etc.) are in trials. Eligibility depends on cancer type, stage, and prior treatments.

Patients can access advanced cancer treatments in China through CancerCareE by sending medical reports for evaluation, consulting with oncologists, participating in clinical trials, and getting referrals to specialized cancer centers in China.